Form 4: Enavate Sciences GP, LLC and Everest Aggregator, LP Report Changes in Beneficial Ownership of Camp4 Therapeutics Corp (CAMP) Stock

Enavate Sciences GP, LLC and Everest Aggregator, LP report transactions involving Camp4 Therapeutics Corp stock, including conversion of preferred stock and open market purchases.

Summary

• On October 15, 2024, Enavate Sciences GP, LLC, through Everest Aggregator, LP, converted 27,166,530 shares of Series B Preferred Stock into 2,422,166 shares of Common Stock of Camp4 Therapeutics Corp.
• Additionally, Everest Aggregator, LP purchased 1,363,636 shares of Common Stock at a price of $11 per share, resulting in a total beneficial ownership of 3,785,802 shares.
• Enavate Sciences GP, LLC, as the general partner of Everest Aggregator, LP, may be deemed to share voting and investment power over these shares but disclaims beneficial ownership except to the extent of its pecuniary interest.

Sentiment

Score: 5

Explanation: This is a neutral report of transactions. The conversion of preferred stock and open market purchase are standard activities.

Management Comments

• Enavate disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders, providing transparency to the market regarding their transactions in the company's stock.

Stakeholder Impact

• The transactions reported may influence investor perception of Camp4 Therapeutics Corp.

Key Dates